Australia Suspends Breast Implants Over Cancer Risk Fears
Conditions have also been imposed on sponsors of products on the market
The Therapeutic Goods Administration has now decided to take regulatory action on breast implants and tissue expanders following its review into the link between these products and a rare type of cancer.
You may also be interested in...
Allergan PLC announced that it would take its Biocell textured breast implants and tissue expanders off the market worldwide shortly after the US FDA released additional information linking the use of the implants to a rare cancer.
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.